新型新辅助化疗后乳腺癌预后分期系统
研究利用美国国家癌症数据库2010至2018年接受新辅助化疗的140,605例患者,按无反应、部分反应和病理完全反应(pCR)三类构建并验证新辅助化疗后预后分期系统。结果显示各验证模型在分期分配上均有统计学显著的生存差异,pCR者94.2%被归为ypStage I,无反应者仅35.5%被归为ypStage I。
要点
- 基于140,605例新辅助化疗患者构建并验证了新辅助化疗后预后分期系统。
- pCR患者中94.2%被归为ypStage I,无反应患者中仅35.5%被归为ypStage I。
- pCR时临床分期进展对总生存影响小,无反应时对三阴性或HER2+乳腺癌影响显著。
核心结论
- 研究提出并验证了一种根据新辅助化疗反应预测总生存的新型预后分期系统,可为越来越多接受新辅助化疗的患者提供AJCC分期分配。
研究设计与样本
- 研究查询美国国家癌症数据库,识别2010年至2018年间接受新辅助化疗的140,605例患者。
- 根据临床分期与新辅助化疗后病理分期的比较,划分无反应、部分反应和病理完全反应(pCR)三个反应类别。
- 对每个反应类别分析临床分期、雌激素受体、孕激素受体、人表皮生长因子受体2(HER2)和分级,并使用bootstrap技术验证预测模型。
- 通过校准图比较训练集和验证集中预测与观察的3年生存概率。
主要发现
- 每个验证模型在新辅助化疗后预后分期分配上均显示统计学显著的生存差异。
- 所有pCR患者中94.2%被归为新辅助化疗后ypStage I,而无反应患者中仅35.5%被归为ypStage I。
- pCR时临床分期进展对总生存影响渐进但较小(高级别三阴性乳腺癌:cStage I为97% vs cStage IIIB/IIIC为91%;2级luminal A型:97% vs 91%)。
- 无反应时临床分期进展与三阴性或HER2+乳腺癌总生存大幅下降相关(高级别三阴性乳腺癌89% vs 50%),2级luminal A型无反应者下降较小(97% vs 81%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prognostic staging after neoadjuvant chemotherapy (NACT) is not included in American Joint Commission on Cancer (AJCC) staging. This study addressed this deficiency by including responses to therapy with standardized staging variables in a validated prognostic staging system for patients treated with NACT. METHODS: The National Cancer Database was queried to identify 140,605 patients treated with NACT between 2010 and 2018. Three response categories (no response, partial response, and complete response [pCR]) were created on the basis of comparison of clinical and post-NACT pathologic staging. Univariate and multivariate analyses of clinical stage, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and grade were analyzed for each category. Predictive models for each response category were validated using the bootstrap technique. Calibration plots compared predicted and observed 3-year survival probabilities in the training and validation data sets. RESULTS: Each validated model demonstrated statistically significant survival differences in the postneoadjuvant prognostic stage assignment. Of all patients with a pCR, 94.2% were assigned to postneoadjuvant ypStage I compared with 35.5% of patients with no response. Advancing clinical stage had a progressive but small impact on overall survival (OS) with pCR (high-grade, triple-negative breast cancer [TNBC]: cStage I, 97% v cStage IIIB/IIIC, 91%; grade 2 luminal A: 97% v 91%) but was associated with a profound decrease in OS with no response for TNBC or HER2+ disease (high-grade TNBC 89% v 50%) and less profound for grade 2 luminal A disease with no response (97% v 81%). CONCLUSION: We present a novel, validated prognostic staging system that predicts OS according to the response to NACT. These data will provide AJCC stage assignments for a growing proportion of patients treated with NACT.
引用
- Winchester DJ, Singh L, Edge SB, et al. Novel Postneoadjuvant Prognostic Breast Cancer Staging System. J Clin Oncol. 2025. PMID: 40215445. doi:10.1200/JCO-24-01739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。